A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy

American Journal of Gastroenterology

Volumn 108, Issue 9, 2013, Pages 1458-1463

  Sharma, Barjesh Chander ^a   Sharma, Praveen ^b   Lunia, Manish Kumar ^a   Srivastava, Siddharth ^a   Goyal, Rohit ^a   Sarin, S K ^b  

^a G B PANT HOSPITAL   (India)

^b INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

LACTULOSE; PLACEBO; RIFAXIMIN;

ABDOMINAL PAIN; ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; UNSPECIFIED SIDE EFFECT;

ADULT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; LACTULOSE; LENGTH OF STAY; MALE; MIDDLE AGED; RIFAMYCINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84883744232     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.219     Document Type: Article

References (24)

1. Ferenci P , Lockwood A , Mullen K et al. Hepatic encephalopathy defi nition, nomenclature, diagnosis, and qualifi cation: fi nal report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002 ; 35 : 716-21.
2. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2006 ; 25 : 3-9.
3. Bustamante J , Rimola A , Ventura PJ et al. Prognostic signifi cance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999 ; 30 : 890-5.
4. Mortensen PB. The Effect of oral administrated lactulose on colonic nitrogen metabolism and excretion. Hepatolgy 1992 ; 16 : 1350-6.
5. Als-Nielsen B , Gluud LL , Gluud C. Non absorbable diasacchardes for hepatic encephalopathy: systemic review of randomised trials. BMJ 2004 ; 328 : 1046.
6. Gerard L , Garey KW , DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005 ; 3 : 201-11.
7. Debbia EA , Maioli E , Roveta S et al. Effects of rifaximin on bacterial virulence mechanisms at supra and subinhibitory concentrations. J Chemother 2008 ; 20 : 186-94.
8. Bass Nm , Mullen KD , Sanyal A et al. Rifaximin treatment in hepatic encephalopathy. N Eng J Med 2010 ; 362 : 1071-81.
9. Bucci L , Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993 ; 13 : 109-18.
10. Paik YH , Lee KS , Han KH et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005 ; 46 : 399-407.
11. Mas A , Rod é s J , Sunyer L et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003 ; 38 : 51-8.
12. Miglio F , Valpiani D , Rossellini SR et al Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy: a double blind, randomised trial. Curr Med Res Opin 1997 ; 13 : 593-601.
13. Jiang Q , Jiang XH , Zheng MH et al. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a metaanalysis. Eur J Gastroenterol Hepatol 2008 ; 20 : 1064-70.
14. Lawrence KR , Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy 2008 ; 28 : 1019-32.
15. Maclayton DO , Eaton-Maxwell A. Rifaximin for treatment of hepatic encephalopathy. Ann Pharmacother 2009 ; 43 : 77-84.
16. Giacomo F , Francesco A , Michele N et al. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993 ; 4 : 57-66.
17. Festi D , Mazzella G , Orsini M et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of effi cacy and safety. Curr Ther Res Clin Exp 1993 ; 54 : 598-609.
18. Eltawil KM , Laryea M , Peltekian K et al. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol 2012 ; 18 : 767-77.
19. Conn HO , Leevy CM , Vlahcevic ZR et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. Gastroenterology 1977 ; 72 : 573-83.
20. Atterbury CE , Maddrey WC , Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978 ; 23 : 398-406.
21. Bauer TM , Schwacha H , Steinbruckner B et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol 2002 ; 97 : 2364-70.
22. Gupta A , Dhiman RK , Kumari S et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010 ; 53 : 849-55.
23. Lunia MK , Sharma BC , Sachdeva S. Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and lowgrade hepatic encephalopathy. Hepatol Int 2013 ; 7 : 268-73.
24. Ojetti V , Lauritano EC , Barbaro F et al. Rifaximin pharmacology and clinical implication. Expert Opin Drug Meta Toxicol 2009 ; 5 : 675-82.